HYCAMTIN 0.25 MG

Država: Izrael

Jezik: angleščina

Source: Ministry of Health

Kupite ga zdaj

Navodilo za uporabo Navodilo za uporabo (PIL)
13-01-2021
Lastnosti izdelka Lastnosti izdelka (SPC)
13-01-2021
Javno poročilo o oceni Javno poročilo o oceni (PAR)
17-08-2016

Aktivna sestavina:

TOPOTECAN AS HYDROCHLORIDE

Dostopno od:

NOVARTIS ISRAEL LTD

Koda artikla:

L01XX17

Farmacevtska oblika:

HARD GELATIN CAPSULES

Sestava:

TOPOTECAN AS HYDROCHLORIDE 0.25 MG

Pot uporabe:

PER OS

Tip zastaranja:

Required

Izdeluje:

GLAXO SMITH KLINE MANUFACTURING S.P.A., ITALY

Terapevtska skupina:

TOPOTECAN

Terapevtsko območje:

TOPOTECAN

Terapevtske indikacije:

Indicated for the treatment of patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.

Datum dovoljenje:

2014-07-31

Navodilo za uporabo

                                PATIENT LEAFLET IN ACCORDANCE WITH THE
PHARMACISTS’ REGULATIONS
(PREPARATIONS) – 1986
The medicine is dispensed according to a
physician’s prescription only
HYCAMTIN
® 0.25 MG
HYCAMTIN
® 1 MG
Hard gelatin capsules
THE ACTIVE INGREDIENT AND ITS QUANTITY:
Each Hycamtin 0.25 mg capsule contains
0.25 mg Topotecan (as Hydrochloride).
Each Hycamtin 1 mg capsule contains 1 mg
Topotecan (as Hydrochloride).
List of the additional ingredients detailed in
section 6.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE
USING THE MEDICINE. This leaflet contains
concise information about the medicine. If you
have any other questions, refer to the physician
or the pharmacist.
This medicine has been prescribed for you. Do
not pass it on to others. It may harm them even
if it seems to you that their medical condition
is similar.
1. WHAT IS THE MEDICINE INTENDED
FOR?
HYCAMTIN IS USED TO TREAT:
patients with relapsed small cell lung cancer
(SCLC) for whom retreatment with the first-line
regimen is not considered appropriate.
Your physician will decide with you whether
Hycamtin therapy is better than further
treatment with your initial chemotherapy.
THERAPEUTIC GROUP
Antineoplastic agent
2. BEFORE USING THE MEDICINE
DO NOT USE THE MEDICINE:
∙ IF YOU ARE SENSITIVE (ALLERGIC) to topotecan
or to any of the additional ingredients
contained in the medicine (listed in Section
6).
∙ Do not use the medicine if you are BREAST-
FEEDING.
∙ IF YOUR BLOOD CELL COUNTS ARE TOO LOW.
Your physician will tell you whether this is
the case, based on the results of your last
blood test.
TELL YOUR PHYSICIAN if any of these applies
to you.
SPECIAL WARNINGS REGARDING THE USE OF THE
MEDICINE
BEFORE THE TREATMENT WITH HYCAMTIN, TELL
THE PHYSICIAN IF:
∙ YOU HAVE ANY KIDNEY OR LIVER PROBLEMS.
Your dose of Hycamtin may need to be
adjusted.
∙ YOU ARE PREGNANT OR ARE PLANNING TO
BECOME PREGNANT (see "Pregnancy and
breast-feeding" section).
∙ YOU PLAN TO FATHER A CHILD (see "Pregnancy
and breast-feeding" section).
TELL YOUR PHYSICIAN if any of these applie
                                
                                Preberite celoten dokument
                                
                            

Lastnosti izdelka

                                [לוגו מדינת ישראל] [http://www.gov.il/]
[http://www.gov.il/] [לוגו משרד הבריאות] [לוגו משרד
הבריאות] [*5400]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
הציבור הרחב עסקים ומוסדות עובדים
בבריאות חפש מידע
תפריט	*
[סגירה]
סגור	*
דף הבית [http://www.health.gov.il/]	*
אודות	*
אודות המשרד
[http://www.health.gov.il/About/Pages/about_us.aspx]	*
תוכנית עבודה
[http://www.health.gov.il/About/Pages/Agenda.aspx]	*
תקציב המשרד
[http://www.health.gov.il/About/Pages/budget.aspx]	*
תרשים מבנה ארגוני
[http://www.health.gov.il/About/Pages/OrganizationalStructureDiagram.aspx]	*
בעלי תפקידים
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx]	*
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx]	*
לשכות הבריאות
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx?tab=3]	*
אמנת שירות
[http://www.health.gov.il/About/sla/Pages/default.aspx]	*
אותות ופרסים
[http://www.health.gov.il/About/Awards/Pages/mifal.aspx]	*
פרוייקטים תשתיתיים
[http://www.health.gov.il/About/projects/shared_medical_info/Pages/default.aspx]	*
דרושים
[http://www.health.gov.il/About/Careers/Pages/default.aspx]	*
מנכ"לי משרד הבריאות לדורותיהם
[http://www.health.gov.il/About/Pages/GeneralManegerHistory.aspx]	*
יחידות המשרד	*
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx]	*
לשכות הבריאות
[http://www.health.gov.il/UnitsOffice/LB/Pages/default.aspx]	*
וועדות ומועצות
[http://www.health.gov.il/Services/Committee/Pages/CommitteeList.aspx]	*
נושאים	*
בריאות הנפש
[http://www.health.gov.il/Subjects/mental_health/Pages/default.aspx]	*
בריאות הסביבה
[http://www.health.gov.il/Subjects/Environmental_Health/
                                
                                Preberite celoten dokument
                                
                            

Dokumenti v drugih jezikih

Navodilo za uporabo Navodilo za uporabo arabščina 13-01-2021
Navodilo za uporabo Navodilo za uporabo hebrejščina 13-01-2021

Opozorila o iskanju, povezana s tem izdelkom

Ogled zgodovine dokumentov